STAT+: Longevity startup NewLimit raises $435 million ahead of first clinical trial

STAT PlusBiotech Longevity startup NewLimit raises $435 million ahead of first clinical trial South San Francisco-based startup has been grabbing investors’ attention Manage alerts for this article Email this article Share this article By Allison DeAngelisJune 2, 2026 Biotech Startups and Venture Capital Reporter Allison DeAngelis[email protected]Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis.01. Longevity startup NewLimit plans to launch its first clinical trial of a liver medicine after raising a staggering $435 million in new funding. NewLimit announced its plans and Series C fundraising Tuesday. Founders Fund, the noted Silicon Valley venture capital firm co-founded by Peter Thiel, led the financing, which also included Thrive Capital, Lilly Ventures, and money from tech entrepreneurs Nat Friedman and Daniel Gross. The company is now valued at around $3.1 billion, according to co-founder and CEO Jacob Kimmel. Advertisement NewLimit was founded in 2021 by Coinbase CEO and co-founder Brian Armstrong, former GV partner and bioengineer Blake Byers, and Kimmel, a stem cell biologist. The South San Francisco-based startup has been moving rapidly, and grabbing investors’ attention. This is the third time in the last year that the company has announced it has raised money from investors — first, a $130 million Series B round in May 2025, followed by another $45 million in October. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In aging, biotechnology, chronic diseases, Pharmaceuticals, STAT+ Submit a correction requestReprints Allison DeAngelis Biotech Startups and Venture Capital Reporter Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis.01. Newsletter Your morning rundown of the science, politics, and money driving biotech today Recommended The Readout June 2, 2026 STAT Plus: Radiopharmaceutical shows promise in post-Pluvicto setting Biotech June 1, 2026 STAT Plus: Abivax ulcerative colitis drug shows strong efficacy, but cases of cancer raise concerns Advertisement Biotech June 1, 2026 STAT Plus: At ASCO, talk of barriers to cancer care, new treatments, and other big takeaways The Readout June 1, 2026 STAT Plus: A turning point for pancreatic cancer patients Biotech June 1, 2026 STAT Plus: Servier to buy Edgewise Therapeutics’ muscular dystrophy drug Subscriber Picks